Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Treating Anemia in Myelofibrosis with Repurposed Drugs (Nelfinavir) that Restore Iron Delivery to the Bone Marrow

Cancer
Angela Fleischman
Other Hematopoietic

Study Description

The purpose of this research study is to test the safety and efficacy of an experimental drug, Nelfinavir, in patients with myelofibrosis (MF) with anemia. Myelofibrosis is an uncommon type of blood cancer where your bone marrow is replaced by fibrosis (scar tissue). The build up of fibrosis can cause anemia, low levels of healthy red blood cells to carry oxygen throughout your body. The current standard treatments for MF is known to worsen anemia. This study is looking to investigate whether using Nelfinavir, can be help treat both anemia and fibrosis in these patients. We also want to find out what effects, good and/or bad, it has on you and your blood cancer.

Nelfinavir is not currently Food and Drug Administration (FDA) approved for use in MF patients and the use is considered investigational in this study.

Eligibility

You can participate in this study if you are:

• At least 18 years of age

• Have a diagnosis of myelofibrosis (MF) and are anemic

You cannot participate in this study if you:

• Unable to do activities of daily living independently

• Currently pregnant or planning on being pregnant within the study period

• Are allergic to Nelfinavir

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.